M&A Deal Summary |
|
|---|---|
| Date | 2018-10-15 |
| Target | Dr. Reddy s Laboratories - API manufacturer |
| Sector | Life Science |
| Buyer(s) | Therapiva Pvt. |
| Sellers(s) | Dr. Reddy s Laboratories |
| Deal Type | Divestiture |
SEARCH BY
Therapiva Pvt. Ltd. has an API manufacturing facility in the city of Hyderabad focused on handling new, complex and hazardous reactions. Therapiva supplies NCEs, cGMP intermediates and KSMs to global innovators. It is equipped with flexible, versatile and advanced infrastructure, tailored to fit any complex chemistry molecules churning out of Innovator’s development pipelines.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: India M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1984 |
| Sector | Medical Products |
| Employees | 27,811 |
| Revenue | 325.5B INR (2025) |
Dr. Reddy’s Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. Dr. Reddy's Laboratories was founded in 1984 and is based in Hyderabad, Telangana.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 4 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 4 |
| Country: India M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-08-19 |
Perlecan Pharma
Hyderabad, India Perlecan Pharma is India's first integrated drug development company and is promoted by Dr. Reddy's Laboratories Limited (DRL) with equity capital commitment from ICICI Venture and other investors. The capital committed is to be used for funding R&D, clinical development and drug filing costs of 4 molecules. Perlecan Pharma has in-licensed 4 NCEs (New Chemical Entities) in the area of Cardiovascular and Metabolic disorders from DRL. The company's key objective is to advance the clinical development of NCE assets through Phase II and thereafter seek out-licensing, co-development or joint commercialization opportunities. Perlecan Pharma was founded in 2005 and is based in Hyderabad, India. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-04-02 |
SERNIVO Spray
Malvern, Pennsylvania, United States SERNIVO Spray is used to treat a type of skin condition (plaque psoriasis). Betamethasone reduces the swelling, itching, and redness that may occur with plaque psoriasis. |
Sell | - |
